The US Food and Drug Administration has approved a landmark new drug for Hunter syndrome, a rare and devastating genetic disease that affects around 500 Americans and causes progressive damage to the brain and other organs. The drug, Avlayah — developed by Denali Therapeutics and known chemically as tividenofusp alfa-eknm — was approved on 25 March 2026 and represents the first treatment ever cleared by the FDA to specifically address the neurological complications of the condition.
What Is Hunter Syndrome?
Hunter syndrome, also known as Mucopolysaccharidosis type II or MPS II, is a rare X-linked genetic disorder caused by a deficiency of the enzyme iduronate-2-sulfatase (IDS). Without this enzyme, certain complex sugars called glycosaminoglycans — specifically heparan sulfate and dermatan sulfate — accumulate in cells throughout the body, causing progressive damage to multiple organ systems.
The condition primarily affects males and typically becomes apparent in early childhood, with symptoms including developmental delays, coarsening of facial features, joint stiffness, hearing loss, recurrent respiratory infections, and — in the more severe form — progressive neurological deterioration that affects cognitive function, behaviour, and ultimately the ability to perform basic tasks. The severe form of Hunter syndrome is associated with a significantly shortened life expectancy, with many affected individuals not surviving beyond their teens or early twenties.
Approximately 500 Americans are affected, with an estimated 2,000 cases worldwide. Because it is an X-linked condition — passed through the X chromosome — it overwhelmingly affects boys and men, though females can be carriers.
What Makes Avlayah Different
Existing treatments for Hunter syndrome involve enzyme replacement therapy, in which the missing IDS enzyme is delivered intravenously on a regular basis. These treatments — including drugs like idursulfase — can manage some of the physical symptoms of the condition, but they have a fundamental limitation: the blood-brain barrier. This protective membrane prevents most large molecules, including conventional enzyme replacement therapies, from crossing from the bloodstream into the central nervous system.
As a result, existing treatments have been unable to address the neurological deterioration that defines the most severe form of Hunter syndrome, leaving patients and families facing progressive cognitive and behavioural decline with no effective pharmacological option.
Avlayah has been specifically engineered to cross the blood-brain barrier. It uses a targeting technology developed by Denali Therapeutics that allows the drug to be transported across the barrier using receptors naturally present on cells lining the brain’s blood vessels. Once inside the central nervous system, the drug can deliver the missing enzyme where it is needed most.
The Clinical Trial Results
The FDA approval was supported by results from a Phase 1/2 clinical trial that demonstrated Avlayah’s significant impact on a key biomarker of Hunter syndrome severity. Patients treated with the drug experienced an average 91 percent decrease in cerebrospinal fluid heparan sulfate levels — the toxic sugar that accumulates in the brain and drives neurological damage. Ninety-three percent of patients achieved normal heparan sulfate levels in cerebrospinal fluid by week 24 of treatment.
While the trial was not large enough to fully establish long-term cognitive outcomes, the biomarker results were sufficiently compelling — and the unmet need sufficiently acute — for the FDA to grant approval. The agency used its accelerated approval pathway, which allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit.
What This Means for Families
For families living with severe Hunter syndrome, the approval of Avlayah represents something that has been hoped for over many years: a drug that can reach the brain and potentially slow or halt the neurological deterioration that robs children of their cognitive abilities. While Avlayah is not a cure, its ability to normalise cerebrospinal fluid markers in the majority of treated patients offers genuine hope that the progression of the disease can be meaningfully slowed.
Patient advocacy organisations for MPS II welcomed the approval warmly, noting that the rare disease community — which often lacks the market size to attract major pharmaceutical investment — has waited a long time for a treatment that addresses the neurological dimensions of the condition.
Denali Therapeutics and the Road Ahead
Denali Therapeutics, a San Francisco-based biopharmaceutical company, has built its research programme around the challenge of crossing the blood-brain barrier — one of the fundamental obstacles in treating neurological diseases. The approval of Avlayah validates that approach and may have implications beyond Hunter syndrome, potentially opening pathways for treating other lysosomal storage disorders that cause neurological damage.
For the roughly 500 Americans affected by Hunter syndrome and their families, 25 March 2026 marks a historic milestone: the day science finally reached the part of the disease that has been most difficult to treat.